Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07937215
NA

Silica-Based Wound Treatment (Curi01) Plus Standard Care Versus Standard Care Alone for Chronic Diabetic Foot Wounds

Sponsor: Cutempa Medical AG

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if Curi01, a powder made of silica (silicon dioxide) particles, helps chronic, oozing diabetic foot ulcers heal when it is added to standard wound care. Curi01 is sprinkled directly onto the wound, where it soaks up wound fluid and forms a gel that is washed off at the next dressing change. The main questions it aims to answer are: Do more wounds heal completely within 12 weeks when Curi01 is added to standard wound care, compared with standard wound care alone? A wound counts as healed when it is fully closed and still closed 14 days later. Is Curi01 safe and well tolerated? Researchers will compare Curi01 plus standard wound care to standard wound care alone. Standard wound care includes removing dead tissue, cleaning the wound, non-medicated dressings and pressure relief for the foot if applicable. Participants will: Be adults with type 1 or type 2 diabetes who have an oozing foot ulcer (2 to 10 cm²) that has been present for at least 6 weeks and has not improved enough with standard wound care First receive standard wound care for 2 weeks to check whether the wound improves on its own Then be assigned by chance to one of the two groups; 2 out of 3 participants will receive Curi01 Visit the study site up to 18 times over about 14 weeks; in the Curi01 group, the powder is applied at each visit until the wound is dry Have their wound photographed and measured with a wound imaging app at each visit Answer questionnaires about their quality of life and how they feel their condition has changed Be asked about any side effects or health problems About 280 participants will take part at around 20 study sites in Germany. Participants and doctors will know which treatment is being given.

Official title: A Randomized, Controlled Clinical Study to Investigate the Efficacy and Safety of a Physically Active SiO2-Aerosil Mixture (Curi01) in Addition to Standard of Care Versus Standard of Care Only in the Treatment of Chronic, Exudating Foot Wounds in Diabetic Patients (DFU)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

280

Start Date

2026-08-20

Completion Date

2028-02

Last Updated

2026-11-18

Healthy Volunteers

No

Interventions

DEVICE

Curi01

Sterile, powder-based wound exudate adsorbing agent composed of two types of silicon dioxide particles. Applied topically to the target wound evenly and generously (layer of approx. 3-5 mm) until the wound surface is completely covered, then covered with a sterile dressing. Applied at each study visit for up to 12 weeks; may be stopped once the wound is dry and restarted if exudation resumes. Class IIb medical device, not CE-marked (investigational).

OTHER

Standard of Care

Standard wound care as defined in the protocol: debridement (sharp/surgical or mechanical) as needed, wound cleansing with sterile saline or an approved antiseptic (polyhexanide, octenidine or chlorhexidine), non-active wound dressings without antimicrobial, pharmacologic or biological agents, offloading if applicable, and compression therapy if indicated.

Locations (13)

Diabetes Zentrum Bad Mergentheim

Bad Mergentheim, Germany

Studienzentrum Dr. Braun GmbH

Berlin, Germany

Klinikum Bremerhaven Reinkenheide gGmbH

Bremerhaven, Germany

Klinikum Chemnitz gGmbH

Chemnitz, Germany

DZDM - Diabetes Zentrum Duisburg Mitte

Duisburg, Germany

Universitätsklinikum Gießen und Marburg, Standort Gießen

Giessen, Germany

Hausarztzentrum Butendorf

Gladbeck, Germany

KRH Klinikum Siloah, Diabetologisches Fuß- und Wundzentrum

Hanover, Germany

Universitätsklinikum Jena

Jena, Germany

Diabetespraxis Kiel

Kiel, Germany

LMU Klinikum, Sektion Angiologie

München, Germany

Gemeinschaftspraxis Dres. Großkopf

Wallerfing, Germany

Helios Klinik Wuppertal, Zentrum für Dermatologie, Allergologie und Dermatochirurgie

Wuppertal, Germany